JAK2 and myeloid leukemia: The mechanism for this is likely due to the dual inhibition of phosphorylated forms of JAK2 and STAT3 thereby reducing STAT3 transcriptional activity, as has been shown for several cancer cell lines including glioma [17], [28], [29], myeloid leukemia [30], and melanoma [20].